Comparison of continuous and intermittent exercise in patients with interstitial lung disease (ILD)
Not Applicable
Not yet recruiting
- Conditions
- Interstitial lung disease (ILD).Other interstitial pulmonary diseases with fibrosisJ84.1
- Registration Number
- IRCT20160516027929N12
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Age older than 18
Consent to participate in the study
BMI in the range of 19 to 25
Muscle force of hip flexors and knee extensors at least 4 out of 5
Patients under oxygen therapy
Exclusion Criteria
Pulmonary hypertension
PAP above 40
Musculoskeletal problems limiting exercise
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PImax. Timepoint: The first day of training and the final day. Method of measurement: Body box.;PEmax. Timepoint: The first day of training and the final day. Method of measurement: Body box.;FEV1. Timepoint: The first day of training and the final day. Method of measurement: Spirometry.;FVC. Timepoint: The first day of training and the final day. Method of measurement: Spirometry.;TLC. Timepoint: The first day of training and the final day. Method of measurement: Spirometry.;Maximum sports capacity. Timepoint: The first day of training and the final day. Method of measurement: Six-minute walk test.;Shortness of breath. Timepoint: The first day of training and the final day. Method of measurement: Based on the Borg scale.;CRP. Timepoint: The first day of training and the final day. Method of measurement: Evaluation of laboratory tests.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the benefits of continuous vs. intermittent exercise in ILD patients awaiting lung transplantation?
How does interval training compare to continuous exercise in improving respiratory function markers in ILD patients with pulmonary fibrosis?
What inflammatory biomarkers are most responsive to exercise interventions in ILD patients with J84.1 classification?
Are there specific adverse events associated with continuous or intermittent exercise regimens in ILD patients undergoing pre-transplant conditioning?
What combination therapies or pharmacological agents synergize with exercise interventions to improve outcomes in ILD patients with fibrotic lung disease?